Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2371 • ACR Convergence 2024
The Role of Intracytoplasmic Toll- Like Receptors (TLR) and MyD88 in B Cell Subsets as Renal Response Predictors in Patients with Lupus Nephritis
Fabiola Cassiano-Quezada¹, José Jiram Torres-Ruiz², Jennifer Balderas Miranda³, José Luis Maravillas-Montero⁴, Karina Santana-de Anda², Beatriz Alcalá-Carmona⁵, Nancy R Mejía-Domínguez⁵, Yatzil Reyna-Juárez⁵, María José Ostos-prado⁵, Guillermo Juarez-Vega⁴ and Diana Gomez-martin⁶, ¹Department of Internal Medicine. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ²Departament of Immunology and Rheumatology. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ³Universidad Nacional Autónoma de México, Ciudad de México, Mexico, ⁴Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ⁶INCMNSZ, Mexico City, Federal District, Mexico
Background/Purpose: Recently, a gain of-function mutation within TLR7 was identified to induce SLE in a murine model and increased the survival of activated B lymphocytes,…
Abstract Number: 2388 • ACR Convergence 2024
Racial/Ethnic Variation in Multimorbidity Risk and Accrual and Comorbid Conditions Among Patients with Systemic Lupus Erythematosus
Katrina Williamson¹, Herbert Heien², Maria Stevens², Cynthia Crowson², Rozalina McCoy² and Ali Duarte-Garcia², ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have been shown to have increased burden of multimorbidity. Racial disparities in multimorbidity have also been shown repeatedly.…
Abstract Number: 2408 • ACR Convergence 2024
Impact of Pain and Fatigue on Quality of Life Among Patients with Systemic Lupus Erythematosus
Amanda Eudy¹, Megan Clowse², Meenakshi Jolly³, David Pisetsky⁴, Kai Sun⁵, Rebecca Sadun⁵, Lisa Criscione-Schreiber⁶, Mithu Maheswaranathan⁶, Jayanth Doss⁵ and Jennifer Rogers⁶, ¹Duke University, Raleigh, NC, ²Duke University, Chapel Hill, NC, ³Rush University Medical Center, Chicago, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Duke University, Durham
Background/Purpose: Our prior qualitative work discovered a subgroup of patients with SLE who experience persistent symptoms of fatigue and widespread pain, even on self-described “good…
Abstract Number: 2424 • ACR Convergence 2024
Anifrolumab Effects on Response to Influenza Vaccine in SLE
Cristina Arriens¹, Anca Askanase², Wambui Machua³, Fotios Koumpouras⁴, Ken Smith¹, Joel Guthridge¹, Judith James¹ and Joan Merrill⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Columbia University Medical Center, New York, NY, ³Piedmont Hospital Center, Atlanta, GA, ⁴Yale School of Medicine, New Haven, CT, ⁵Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: Risk for infections in systemic lupus may arise from immunosuppressant treatments or intrinsic immune defects. Disordered interferon signals are a hallmark of SLE. Anifrolumab, which…
Abstract Number: 2545 • ACR Convergence 2024
Phosphodiesterase 1B Contributes to Neuropsychiatric Manifestations in Lupus-Prone Mice Through Microglial Activation
Shuhei Takeyama¹, Michihito Kono¹, Kohei Karino¹, Yuki Kudo¹, Masatoshi Kanda², Hiroyuki Nakamura², Kenichi Miyamoto¹, Kazuro Kamada³, Maria Tada¹, Ryo Hisada¹, Yuichiro Fujieda¹, Masaru Kato¹, Olga Amengual⁴ and Tatsuya Atsumi¹, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ²Department of Rheumatology and Clinical Immunology, Sapporo Medical University, Sapporo, Japan, Sapporo, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapprp, Japan, ⁴Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is one of the most severe organ manifestations in SLE and is associated with poor quality of life. We…
Abstract Number: 2605 • ACR Convergence 2024
Clarifying Misbeliefs & Resolving Decisional Conflicts About Hydroxychloroquine (HCQ) Through a Shared Decision-Making Tool (HCQ-SAFE©)
Shivani Garg¹, Jay Patel¹, Sancia Ferguson², Betty Chewning³, Shelby Gomez⁴, Jon keevil⁵, David Gazeley⁶, Patricia Tellez-Giron¹ and Christie Bartels⁷, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²University of Wisconsin, Madison, Madison, WI, ³University of Wisconsin, School of Pharmacy, Madison, ⁴UW Health, Madison, ⁵N/A, Madison, ⁶Medical College of Wisconsin, Wauwatosa, WI, ⁷University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Treatment of lupus (or SLE) is complex, especially for young patients who are committed to take hydroxychloroquine (HCQ) lifelong, which carries some risk, albeit…
Abstract Number: 0093 • ACR Convergence 2024
Overexpression of Epidermal Ifnk Promotes Systemic CD8+ T Cell Maturation After UV-exposure
Benjamin Klein¹, Kelsey E. McNeely², Debbie Colesa², Yiqing Gao², Nguyen Thi Kim Nguyen², Johann Gudjonsson¹ and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Michigan Medicine, Ann Arbor, MI
Background/Purpose: Skin involvement is the most common organ manifestation in systemic lupus erythematosus (SLE), and exacerbation of cutaneous lupus (CLE) can precede systemic disease flares.…
Abstract Number: 0168 • ACR Convergence 2024
Real-world Glucocorticoid Prescription Patterns in Patients with Lupus Nephritis: A Retrospective Study Using a Healthcare Insurance Claims Database
Tatsuya Atsumi¹, Hironari Hanaoka², Nobuo Nishijima³, Kohji Murakami⁴, Mariko Nio³, Tsutomu Urakawa³, Takaaki Fujimura³ and Hiroki Hayashi⁵, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, ⁴Nippon Shinyaku Co., Ltd., Tokyo, Japan, ⁵Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
Background/Purpose: Lupus nephritis (LN) is one of the most frequent organ manifestations of systemic lupus erythematosus (SLE), affecting morbidity and mortality in SLE. LN is…
Abstract Number: 0193 • ACR Convergence 2024
New York City Lupus Clinical Trials Education Program
Maya Souvignier¹, Leila Khalili¹, Wai Yan April Fu², Laura Geraldino³, Nancyanne Schmidt¹, Yevgeniya Gartshteyn⁴, Peter Izmirly⁵, Noa Schwartz⁶ and Anca Askanase¹, ¹Columbia University Medical Center, New York, NY, ²Albert Einstein College of Medicine, New York, NY, ³Division of Rheumatology, Department of Medicine, Columbia University, New York, NY, ⁴Columbia University Irving School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY, ⁶Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY
Background/Purpose: Clinical trial (CT) participation is essential for the advancement of treatment paradigms and should be considered part of clinical care in SLE. CTs fail…
Abstract Number: 0361 • ACR Convergence 2024
Maternal and Fetal Outcomes in Those with Autoimmune Connective Tissue Disease
Nada Alrifai¹, Anushree Puttur², Laith Alhuneafat³, Fares Ghanem⁴, yadhu Dhital², Ahmad Jabri⁵ and David Feinstein⁶, ¹Cooper University Hospital, Cherry Hill, NJ, ²Allegheny Health Network, Pittsburgh, PA, ³University of Minnesota, Minneapolis, MN, ⁴Southern Illinois University, Springfield, IL, ⁵Henry Ford, Detroit, MI, ⁶Cooper University, Camden, NJ
Background/Purpose: Autoimmune connective tissue diseases (CTD) predominantly affect women during their reproductive years. CTDs such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic…
Abstract Number: 0445 • ACR Convergence 2024
Evaluating Clinical Reasoning in Randomized Surveys of Lupus Nephritis and Preeclampsia Pregnancy Case Workups: A Clinical Conundrum
Liya Stolyar¹, Sadaf Sediqi², Richard Lafayette³, Maurice Druzin⁴, Saadiya Hawa⁵, Amanda Moyer⁶, Yashaar Chaichian² and Julia Simard², ¹Palo Alto VA Medical Center/Stanford, Stanford, CA, ²Stanford School of Medicine, Stanford, CA, ³Stanford, Stanford, CA, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Weiss Memorial Hospital, Chicago, IL, ⁶Stanford University, San Bruno, CA
Background/Purpose: Systemic lupus erythematosus (SLE) pregnancy is associated with a heightened risk of adverse pregnancy outcomes, including preeclampsia. Distinguishing preeclampsia from lupus nephritis (LN) presents…
Abstract Number: 0619 • ACR Convergence 2024
Prevalence and Factors Predicting Hemophagocytic Lymphohistiocytosis in Hospitalized Patients with Systemic Lupus Erythematosus
OKEOGHENE AKPOIGBE¹, BETTINA ESCOLANO², ENOCH J ABBEY² and Amanda Sammut³, ¹New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, NY, ²New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, ³New York City Health and Hospitals/Harlem. Rheumatology Department, Chappaqua, NY
Background/Purpose: Systemic lupus erythematosus (SLE) complicated with hemophagocytic lymphohistiocystosis (HLH) can be life-threatening with mortality as high as 9.9%-10.5%. Estimates of the prevalence of HLH…
Abstract Number: 0639 • ACR Convergence 2024
Delayed Diagnosis in Systemic Lupus Erythematosus
Romina Nieto¹, Lucia Hernandez², Nidia Noemí Merás³, Bordón Florencia Juliana⁴, Cintia Otaduy⁵, Lucila Garcia⁶, Rosa Serrano Morales⁷, Nicolás Pérez⁸, Micaela A. Cosatti⁹, Ana Carolina Montandon¹⁰, Gustavo Flores Chapacais¹¹, Laissa C. Alves Alvino¹², Emily Figuereido Neves¹³, Eloisa Bonfa¹⁴, Alexis Bondi Peralta¹⁵, Loreto Massardo¹⁶, Andrés Cadena Bonfanti¹⁷, Andrés Hormaza¹⁸, José Martínez¹⁹, Olga Lidia Vera Lastra²⁰, Hilda Fragoso-Loyo²¹, ⁠Yaneli Juárez-Vicuña²², Diana Fernandez²³, Patricia Langjarth²⁴, Maria Teresa Martinez de Filartiga²⁵, Manuel Ugarte-Gil²⁶, Carlos Alejandro Loayza Flores²⁷, Teresandris Polanco²⁸, Maria Belen Lecumberri²⁹, Álvaro Danza³⁰, Carlos Enrique Toro-Gutierrez³¹, Urbano Sbarigia³², Ashley Orillion³³, Federico Zazzetti³⁴, Graciela Alarcon³⁵, Bernardo Pons-Estel² and Guillermo Pons-Estel³⁶, and Grupo Latino Americano de Estudio del Lupus (GLADEL), ¹Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ³Hospital Italiano de Córdoba, Cordoba, Argentina, ⁴Hospital Privado Universitario de Córdoba, Córdoba, Argentina, ⁵Hospital Córdoba, Cordoba, Spain, ⁶Servicio de Reumatología del HIGA San Martín, La Plata, Argentina, ⁷Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁸Instituto de Investigaciones Médicos Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, ⁹CEMIC Centro de Educación Médica e Investigaciones Clínicas ''Norberto Quirno'' CABA, CABA, Argentina, ¹⁰Hospital das Clinicas, Universidad Federal de Goias, Goias, Brazil, ¹¹Rheumatology Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹²Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, ¹³Hospital da Clinicas de Sao Paulo, São Paulo, SP, Brazil, ¹⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ¹⁵Hospital del Salvador, Santiago, Chile, ¹⁶Centro de Biología Celular y Biomedicina CEBICEM, Facultad de Medicina y Ciencias Universidad San Sebastián, Santiago, Chile, ¹⁷Universidad Simon Bolivar, Barranquilla, Colombia, ¹⁸Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ¹⁹Rheumatology Service, Luís Vernaza Hospital, Guayaquil, Ecuador, ²⁰División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ²¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²²Instituto Nacional de Cardiología Ignacio Chávez, Departamento de Inmunología, Investigador en Ciencias Médicas C, Mexico City, Mexico, ²³Member of GLADEL, Rosario, Argentina, ²⁴Hospital de Clínicas I, Asunción, Paraguay, ²⁵Dpto de Reumatología Hospital de Clínicas. Facultad de Ciencias medicas.Universidad Nacional de Asunción, Asuncion del Paraguay, Paraguay, ²⁶Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Científica del Sur. Lima. Perú Servicio de Reumatología. Hospital Guillermo Almenara Irigoyen-EsSalud, Lima, Peru, ²⁷Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ²⁸Hospital Docente Padre Billini, Santo Domingo, Dominica, ²⁹Hospital Señor del Milagro, Salta, Argentina, ³⁰Médica Uruguaya Corporación de Asistencia Médica (MUCAM). Clínica Médica - Facultad de Medicina - UdelaR, Montevideo, Uruguay, ³¹Reference Center for Osteoporosis & Rheumatology, Cali, Colombia, ³²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³³Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ³⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ³⁵The University of Alabama at Birmingham, Oakland, CA, ³⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease of unknown etiology. Diagnosis is often delayed because it frequently mimics symptoms of other diseases;…
Abstract Number: 0656 • ACR Convergence 2024
Lupus Myocarditis: Clinical Characteristics, Cardiac Magnetic Resonance Imaging Findings and Outcomes
María del Carmen Zamora-Medina¹, Erik Cimé-Aké², Emilio G. Lazarini², Wallace Rafael A. Muñoz-Castañeda³ and Hilda Fragoso-Loyo², ¹Instituto Nacional de Perinatología "Isidro Espinoza de los Reyes". Rheumatology Department, Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³Hospital Medica Sur. Rheumatology Department, Mexico City, Distrito Federal, Mexico
Background/Purpose: Limited information about lupus myocarditis (LM) comes from small case series. The aim of our study is to describe and compare clinical characteristics, cardiac…
Abstract Number: 0674 • ACR Convergence 2024
Hydroxychloroquine Screening Adherence: Insights from Highmark Claims Data
Sara Shahid¹, Tyson Barrett², Sonia Manocha¹ and Tanmayee Bichile¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Highmark Health, Pittsburgh, PA
Background/Purpose: Hydroxychloroquine (HCQ)-associated retinal toxicity and vision loss are significant challenges, with a 2% prevalence in patients using HCQ for over 10 years and up…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].